Healthcare provider organizations that hung tight during the dark days of risk contracting are beginning to see a payoff for their persistence, according to a new report.
Healthcare provider organizations that hung tight during the dark days of risk contracting are beginning to see a payoff for their persistence, according to a new report. Respondents to the 2000 Capitation Survey report significantly higher per-member, per-month rates in nearly all categories and specialties.
The survey's findings reflect two concurrent phenomena in the risk-contracting market, according to David Schwartz, publisher of the 2000 Capitation Survey.
"First, rates are simply up," said Schwartz. "Physicians and other providers are finally seeing recent premium increases passed along in their contracts. And second, as poorly performing groups have dropped out of the market, better performers with higher rates are pushing the overall average up." Overall, nearly 70% of respondents report that their rates have increased this year. Rate increases in many specialties featured in the survey are well into the double digits.
The survey also suggests that the widely reported exodus from capitation has been significantly overblown. In fact, 78% of respondents report that they are either seeking more capitation or maintaining their current level of risk agreements.
"Clearly, the oft-reported 'demise' of capitation has been based primarily on high-profile anecdotes, not data," said Schwartz. "Risk contracting is as much a part of most providers' lives as it ever was, and capitation appears to be poised for at least moderate growth in the coming two to three years. In fact, if employers continue to see the kind of premium increases they've seen this year, capitation may make a very big comeback as cost control becomes top priority again." PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.